These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells. Shaik AB; Rao GK; Kumar GB; Patel N; Reddy VS; Khan I; Routhu SR; Kumar CG; Veena I; Chandra Shekar K; Barkume M; Jadhav S; Juvekar A; Kode J; Pal-Bhadra M; Kamal A Eur J Med Chem; 2017 Oct; 139():305-324. PubMed ID: 28803046 [TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents. Peng W; Tu ZC; Long ZJ; Liu Q; Lu G Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents. Amin KM; Eissa AA; Abou-Seri SM; Awadallah FM; Hassan GS Eur J Med Chem; 2013 Feb; 60():187-98. PubMed ID: 23291120 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. Bakr RB; Mehany ABM; Abdellatif KRA Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084 [TBL] [Abstract][Full Text] [Related]
7. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα. Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755 [TBL] [Abstract][Full Text] [Related]
8. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376 [TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies. El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents. Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings. Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429 [TBL] [Abstract][Full Text] [Related]
13. Jinlong capsule inhibits migration and invasion in human glioblastoma cells via the modulation of mTOR/S6 signaling pathway. Shi J; Zhang W; He L; Kong F; Pan M; Guo J; Xu X; Guo J; Wang H; Wang Y Drug Des Devel Ther; 2019; 13():1023-1032. PubMed ID: 31114156 [No Abstract] [Full Text] [Related]
14. 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. Viswanathan A; Kute D; Musa A; Konda Mani S; Sipilä V; Emmert-Streib F; Zubkov FI; Gurbanov AV; Yli-Harja O; Kandhavelu M Eur J Med Chem; 2019 Mar; 166():291-303. PubMed ID: 30731398 [TBL] [Abstract][Full Text] [Related]
15. Design and stereoselective synthesis of novel isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents. Zhu SL; Wu Y; Liu CJ; Wei CY; Tao JC; Liu HM Eur J Med Chem; 2013 Jul; 65():70-82. PubMed ID: 23693151 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives. El-Gamal MI; Abdel-Maksoud MS; Gamal El-Din MM; Shin JS; Lee KT; Yoo KH; Oh CH Anticancer Agents Med Chem; 2017; 17(1):75-84. PubMed ID: 27334850 [TBL] [Abstract][Full Text] [Related]
17. Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils. Bordoloi M; Saikia S; Kolita B; Sarmah R; Roy S; Narzary B Anticancer Agents Med Chem; 2018; 18(1):87-109. PubMed ID: 28356026 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors. Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467 [TBL] [Abstract][Full Text] [Related]
19. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]